Each one in plain English, with the numbers worked through for a shareholder.
29 Jan 2026capital raising announcement▲ GoodMajor
Galan raises A$40M at A$0.41 per share (2% premium to 5-day VWAP), with Clean Elements participating, plus A$1M from directors subject to shareholder approval. Funds expand Phase 1 from 4 to 5.2 ktpa LCE, Greenbushes South exploration and working capital. This is a much higher price than the A$0.11 Clean Elements paid.
Clean Elements pays the second A$10M tranche early, completing its A$20M placement (A$0.11 per share, per the earlier announcement). Galan says Phase 1 is fully funded, with no debt and access to the US$6M Authium prepayment facility. Clean Elements' Ofer Amir will join the board as a non-executive director before year end.
25 Aug 2025capital raising announcement▲ GoodMajor
Clean Elements confirms all conditions met for the A$20M placement, after shareholder approval on 22 August. Tranche 1 (A$10M) settles within five business days; tranche 2 (A$10M) by 22 November 2025. Galan says Phase 1 is now fully funded.
1 Aug 2025capital raising announcement● NeutralMajor
Galan uses its Acuity at-the-market facility to raise A$2M via 15M set-off shares at A$0.133. This reduces Acuity's collateral shares to zero, so the facility cannot be used again; the company does not intend further use in 2025.
20 June 2025capital raising announcement▲ GoodMajor
Galan secures a binding A$20M placement at A$0.11 (21% premium to the A$0.091 close) from existing shareholder Clean Elements, with one A$0.15 three-year option per two shares. Subject to due diligence and shareholder approval; described as final Phase 1 funding. Debt terms were unfavourable.
The share purchase plan raised only A$335,000 from 3,045,436 shares at A$0.11, far below the up to A$4M offered. Shares were issued without using placement capacity.
What it means for a shareholder
3.0m new shares at A$0.110 to raise about A$335,000. Shares on issue before the raise aren't in the record, so the dilution can't be worked out.
Reminder that the share purchase plan closes 6 June 2025 at A$0.11, up to A$30,000 per holder, with instructions on applying via Automic. No new information.
The share purchase plan closing date is extended from 22 May to 6 June 2025, citing mailing delays and alignment with the 5 June general meeting. Price stays A$0.11, max A$30,000 per holder; allotment moves to 12 June.
Offer booklet for the share purchase plan at the A$0.11 placement price (per the 16 April announcement): eligible holders may buy up to A$30,000 of shares, closing 23 May 2025, with allotment on 29 May. The SPP was announced as up to A$4M.
Eighth Acuity at-the-market draw: A$575k from 5.7M shares at A$0.101, an 8.2% discount to the 15-day VWAP, for working capital. A small draw at a lower price than February's A$0.115.
What it means for a shareholder
5.7m new shares at A$0.101 to raise about A$575,000. Shares on issue before the raise aren't in the record, so the dilution can't be worked out.
Seventh Acuity at-the-market draw: A$1.5M from 13M shares at A$0.115, a 0.5% discount to the 15-day VWAP, for working capital. Priced below the A$0.12 draw in December 2024.
What it means for a shareholder
13.0m new shares at A$0.115 to raise about A$1.5m. Shares on issue before the raise aren't in the record, so the dilution can't be worked out.
28 Jan 2025capital raising announcement▲ GoodMajor
Galan received the US$3M Chemphys placement money via affiliate Latam Resources, after shareholders approved it at the 15 November 2024 AGM. Funds go to Phase 1 work. The offtake prepayment facility is still unsigned, targeting close in Q1 2025.
Sixth Acuity at-the-market draw: A$1.8M from 15M shares at A$0.12, equal to the 15-day VWAP, for working capital. The price is above the August A$0.1222 draw but far below the A$0.283 of the first draw in May.
What it means for a shareholder
15.0m new shares at A$0.120 to raise about A$1.8m. Shares on issue before the raise aren't in the record, so the dilution can't be worked out.
16 Oct 2024capital raising announcement▲ GoodMajor
The entitlement offer closed fully subscribed, raising A$13.3M at A$0.105. Eligible holders applied for 60.2M shares and the full 66.5M shortfall was taken up. This completes the A$25M raising begun in September; shares issue 17 October.
What it means for a shareholder
60.2m new shares at about A$0.2209 to raise about A$13.3m. Shares on issue before the raise aren't in the record, so the dilution can't be worked out.
Entitlement offer closing date extended one week to 10 October 2024, with shares to be issued 17 October. Directors cite mailing delays and giving holders time to read the 30 June annual report.
Entitlement offer booklet: 1 new share for every 4 held at A$0.105, raising about A$13.3M before costs, closing 3 October 2024, with a shortfall facility. It is not underwritten and carries risk factors. It repeats the terms already announced.
Letter telling ineligible (mostly overseas) shareholders they cannot take part in the A$0.105 entitlement offer, and their entitlements will lapse with no payment. Administrative; no new terms.
Letter to eligible shareholders on the 1-for-4 non-renounceable entitlement offer at A$0.105, open 18 September to 3 October 2024, with a shortfall facility. Entitlements not taken up lapse without value. It repeats terms already announced.
Galan raises about A$12M via a placement at A$0.105, plus a 1-for-4 entitlement offer for up to A$13.3M at the same price. Chemphys takes about A$4.5M, conditional on definitive agreements. Phase 1 is cut to an initial 4,000tpa LCE; first production stays H2 2025.
Fifth Acuity at-the-market draw: A$600k from 4.8M collateral shares at A$0.125, a 7.1% discount to the 15-day VWAP, for working capital. The issue price is still well below the A$0.283 of the first draw in May.
Fourth Acuity draw in the series: A$1.1M from 9M shares at A$0.1222, a 9.3% discount to the 15-day VWAP, for working capital. The issue price keeps falling from the earlier draws.
What it means for a shareholder
9.0m new shares at A$0.1222 to raise about A$1.1m. Shares on issue before the raise aren't in the record, so the dilution can't be worked out.
Third Acuity draw in the series: A$650k from 4.75M shares at A$0.137, an 11.5% discount to the 15-day VWAP, for working capital. The issue price keeps falling from the earlier draws.
What it means for a shareholder
4.8m new shares at A$0.137 to raise about A$650,000. Shares on issue before the raise aren't in the record, so the dilution can't be worked out.
Second Acuity at-the-market draw: A$1.1M from 7.05M shares at A$0.156, an 8.8% discount to the 15-day VWAP. Collateral shares were topped up to 15M. A$3.35M drawn in total, A$11.65M remains, versus the A$0.283 first draw.
What it means for a shareholder
7.0m new shares at A$0.156 to raise about A$1.1m. Shares on issue before the raise aren't in the record, so the dilution can't be worked out.
Galan has firm commitments for a A$14M placement at A$0.23 per share, a 20.7% discount to the A$0.29 close, with one option (A$0.35, two years) per two shares. Funds support HMW Phase 1 while debt and prepayment funding is negotiated. Directors take about A$1M in a second tranche.
Galan draws on the Acuity facility for the first time, raising A$2.25M by setting off 7.95M collateral shares at A$0.283, a 5.7% discount to the A$0.30 close. That is well below the A$0.46 placement price.
Galan signs a A$15M standby equity facility with Acuity Capital, available until 31 January 2029, at Galan's discretion with no obligation to use it. It issued 15M collateral shares at nil cash as security. Issue price would be at up to a 10% discount to VWAP.
27 Mar 2024capital raising announcement▲ GoodMajor
The Share Purchase Plan drew just over A$4M of applications against a A$1.5M target, and Galan lifted it to A$4.003M. It will issue 8,702,150 shares (2.2% of capital) at A$0.46, each with a free $0.65 option.
Prospectus for the free listed options ($0.65, expiring 20 March 2029) attached to the A$0.46 raising: up to 35.9M for placement investors, 4.8M for directors (subject to approval) and 8.7M for SPP participants. No funds are raised.
The Share Purchase Plan closing date is extended to 22 March 2024, with results due 26 March and shares issued 28 March. A timetable change to the A$0.46 offer; no change to its terms.
Offer letter for the Share Purchase Plan: eligible Australian and New Zealand holders can buy A$2,000-30,000 of shares at A$0.46 with one free $0.65 option each, targeting A$1.5M. It confirms A$16.5M was raised in the placement; the options need a prospectus.